PCF-Pfizer Global Challenge Awards

Organization
Prostate Cancer Foundation (PCF)
Type
Foundation
Application or LOI Due Date
12-03-2019
Comments
LOI required and due 12/3/19
Brief Description

The Prostate Cancer Foundation (PCF) and Pfizer, Inc. are proud to announce the PCF-Pfizer Global Challenge Awards, a competitive, peer-reviewed Investigator Sponsored Research (ISR) grants program.

Approximately $2 million USD is allocated to this research grants program focused on investigating talazoparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, in prostate cancer.

Through this funding mechanism, PCF and Pfizer will support approximately three (3) innovative clinical investigations or clinical trial correlative research studies surrounding the use of talazoparib in prostate cancer.

Applications will be peer-reviewed by an independent review panel led by PCF, composed of expert academic researchers in order to select the most impactful studies for funding. The amount of each award will be determined based on the external review panel’s evaluation of each project.